Appendix A: Key to Acronyms
General Terms
| Acronym/Abbreviation | Definition |
|---|---|
| 17-BMP | beclomethasone 17-monopropionate |
| ACA | Affordable Care Act |
| ADAP | AIDS Drug Assistance Program |
| AE | adverse event |
| Ag/Ab | antigen/antibody |
| AHA | American Heart Association |
| AHC-HRSN | Accountable Health Communities Health-Related Social Needs |
| Al | aluminum |
| ALT | alanine aminotransferase |
| AMP | average manufacturer price |
| aPR | adjusted prevalence ratio |
| ART | antiretroviral therapy |
| ARTAS | Anti-Retroviral Treatment and Access to Services |
| ARV | antiretroviral |
| ASP | average sales price |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUD | alcohol use disorder |
| AUDIT-C | Alcohol Use Disorders Identification Test-Consumption |
| AV | atrioventricular |
| AWP | average wholesale price |
| AYA | adolescents and young adults |
| BMD | bone mineral density |
| BMI | body mass index |
| BMT | bone marrow transplant |
| BUN | blood urea nitrogen |
| Ca | calcium |
| CaCO3 | calcium carbonate |
| CBC | complete blood count |
| CCB | calcium channel blocker |
| CD4 | CD4 |
| CDC | Centers for Disease Control and Prevention |
| CGRP | calcitonin gene-related peptide |
| CHF | congestive heart failure |
| CI | confidence interval capsid inhibitor |
| CKD | chronic kidney disease |
| Cl | chloride |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMS | Centers for Medicare & Medicaid Services |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| COC | combined oral contraceptive |
| CPI-U | consumer price index-urban |
| CPK | creatine phosphokinase |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CsA | cyclosporine |
| CSF | cerebrospinal fluid |
| CV | cardiovascular |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| D/M | dual/mixed |
| DAA | direct-acting antiviral |
| DDI | drug–drug interaction |
| DHA | dihydroartemisinin |
| DILI | drug-induced liver injury |
| DM | diabetes mellitus |
| DMPA | depo-medroxyprogesterone acetate |
| DOAC | direct oral anticoagulant |
| DOT | directly observed therapy |
| DSMB | Data Safety Monitoring Board |
| DVT | deep vein thrombosis |
| EBV | Epstein-Barr virus |
| ECG | electrocardiogram |
| eGFR | estimated glomerular filtration rate |
| ESRD | end-stage renal disease |
| FCP | federal price ceiling |
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| Fe | iron |
| FUL | federal upper limit |
| GAHT | gender-affirming hormone therapy |
| GFR | glomerular filtration rate |
| GHB | gamma-hydroxybutyrate |
| GI | gastrointestinal |
| GnRH | gonadotropin-releasing hormone |
| GVHD | graft versus host disease |
| H2 | histamine type 2 |
| H2RA | H2 receptor antagonist |
| HAND | HIV-associated neurocognitive disorder |
| HAV | hepatitis A virus |
| HbA1C | hemoglobin A1c |
| HBcAb | hepatitis B core antibody |
| HBeAg | hepatitis B e antigen |
| HBsAb | hepatitis B surface antibody |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCC | hepatocellular carcinoma |
| HCO3 | bicarbonate |
| HCT | hematopoietic cell transplant |
| HCV | hepatitis C virus |
| HD | hemodialysis high-dose |
| HDL | high-density lipoprotein |
| HDV | hepatitis D virus |
| HHS | U.S. Department of Health and Human Services |
| HIV | human immunodeficiency virus |
| HIV RNA | HIV viral load |
| HIV-1 | human immunodeficiency virus type 1 |
| HIV-2 | human immunodeficiency virus type 2 |
| HIVMA/IDSA | HIV Medicine Association of the Infectious Diseases Society of America |
| HLA | human leukocyte antigen |
| HMG-CoA | hydroxy-methylglutaryl-coenzyme A |
| HR | hazard ratio |
| HRSA | Health Resources and Services Administration |
| HRT | hormone replacement therapy |
| hs-CRP | high-sensitivity C-reactive protein |
| HSR | hypersensitivity reaction |
| HTLV-1 | human T-lymphotropic virus-1 type I |
| IC50 | median inhibitory concentration |
| IL | interleukin |
| IM | intramuscular |
| IMF | illicitly manufactured fentanyl |
| IN | integrase |
| INR | international normalized ratio |
| INSTI | integrase strand transfer inhibitor |
| IPT | isoniazid preventive therapy |
| IRIS | immune reconstitution inflammatory syndrome |
| ISR | injection site reactions |
| IUD | intrauterine device |
| IV | intravenous |
| K | potassium |
| LA | long-acting |
| LDL | low-density lipoprotein |
| LGBTQ | lesbian, gay, bisexual, transgender, or queer |
| LLOD | lower limits of detection |
| LTBI | latent tuberculosis infection |
| MAC | Mycobacterium avium complex |
| MATE | multidrug and toxin extrusion transporter |
| MDMA | methylenedioxymethamphetamine |
| MDR | multidrug resistant |
| MDR-TB | multidrug-resistant tuberculosis |
| MDRP | Medicaid Drug Rebate Program |
| MET | motivational enhancement therapy |
| Mg | magnesium |
| MHC | major histocompatibility complex |
| MI | motivational interviewing myocardial infarction |
| MPA | medroxyprogesterone acetate |
| MRI | magnetic resonance imaging |
| MSM | men who have sex with men |
| MTR | multi-tablet regimen |
| N/A | not applicable |
| Na | sodium |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside/nucleotide reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OATP | organic anion-transporting polypeptide |
| OBR | optimized background regimen |
| OCT2 | organic cation transporter 2 |
| OH-itraconazole | active metabolite of itraconazole |
| OI | opportunistic infection |
| ONDCP | Office of National Drug Control Policy |
| OR | odds ratio |
| OTP | opioid treatment program |
| OUD | opioid use disorder |
| P | phosphorus |
| P-gp | p-glycoprotein |
| PAH | pulmonary arterial hypertension |
| PBM | pharmacy benefit manager |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PDE5 | phosphodiesterase type 5 |
| PEP | post-exposure prophylaxis |
| PI | protease inhibitor |
| PI/c | cobicistat-boosted protease inhibitor |
| PI/r | ritonavir-boosted protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PPI | proton pump inhibitor |
| PR | protease |
| PRAPARE | Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences |
| PrEP | pre-exposure prophylaxis |
| PTH | parathyroid hormone |
| QTc | QT corrected for heart rate |
| REPC | Retention through Enhanced Personal Contact |
| RNA | ribonucleic acid |
| RT | reverse transcriptase |
| RWHAP | Ryan White HIV/AIDS Program |
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SCr | serum creatinine |
| SDOH | social determinants of health |
| SMR | sexual maturity rating |
| SOT | solid organ transplantation |
| SPT | skin patch test |
| SQ | subcutaneous |
| SSP | syringe service program |
| SSRI | selective serotonin reuptake inhibitor |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| SUD | substance use disorder |
| TasP | treatment as prevention |
| TB | tuberculosis |
| TC | total cholesterol |
| TCA | tricyclic antidepressant |
| TDM | therapeutic drug monitoring |
| TDR | transmitted drug resistance |
| TG | triglyceride |
| The Panel | The Panel on Antiretroviral Guidelines for Adults and Adolescents |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1 | uridine diphosphate glucuronosyltransferase 1 family |
| UGT1A1 | uridine diphosphate glucuronosyltransferase 1A1 |
| ULN | upper limit of normal |
| UW | University of Washington |
| VL | viral load |
| VPA | valproic acid |
| WAC | wholesale acquisition cost |
| WBC | white blood cell |
| WHO | World Health Organization |
| WPATH | World Professional Association for Transgender Health |
| XDR | extensively drug-resistant |
| XR | extended release |
| Zn | zinc |
Appendix A: Key to Acronyms
General Terms
| Acronym/Abbreviation | Definition |
|---|---|
| 17-BMP | beclomethasone 17-monopropionate |
| ACA | Affordable Care Act |
| ADAP | AIDS Drug Assistance Program |
| AE | adverse event |
| Ag/Ab | antigen/antibody |
| AHA | American Heart Association |
| AHC-HRSN | Accountable Health Communities Health-Related Social Needs |
| Al | aluminum |
| ALT | alanine aminotransferase |
| AMP | average manufacturer price |
| aPR | adjusted prevalence ratio |
| ART | antiretroviral therapy |
| ARTAS | Anti-Retroviral Treatment and Access to Services |
| ARV | antiretroviral |
| ASP | average sales price |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUD | alcohol use disorder |
| AUDIT-C | Alcohol Use Disorders Identification Test-Consumption |
| AV | atrioventricular |
| AWP | average wholesale price |
| AYA | adolescents and young adults |
| BMD | bone mineral density |
| BMI | body mass index |
| BMT | bone marrow transplant |
| BUN | blood urea nitrogen |
| Ca | calcium |
| CaCO3 | calcium carbonate |
| CBC | complete blood count |
| CCB | calcium channel blocker |
| CD4 | CD4 |
| CDC | Centers for Disease Control and Prevention |
| CGRP | calcitonin gene-related peptide |
| CHF | congestive heart failure |
| CI | confidence interval capsid inhibitor |
| CKD | chronic kidney disease |
| Cl | chloride |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMS | Centers for Medicare & Medicaid Services |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| COC | combined oral contraceptive |
| CPI-U | consumer price index-urban |
| CPK | creatine phosphokinase |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CsA | cyclosporine |
| CSF | cerebrospinal fluid |
| CV | cardiovascular |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| D/M | dual/mixed |
| DAA | direct-acting antiviral |
| DDI | drug–drug interaction |
| DHA | dihydroartemisinin |
| DILI | drug-induced liver injury |
| DM | diabetes mellitus |
| DMPA | depo-medroxyprogesterone acetate |
| DOAC | direct oral anticoagulant |
| DOT | directly observed therapy |
| DSMB | Data Safety Monitoring Board |
| DVT | deep vein thrombosis |
| EBV | Epstein-Barr virus |
| ECG | electrocardiogram |
| eGFR | estimated glomerular filtration rate |
| ESRD | end-stage renal disease |
| FCP | federal price ceiling |
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| Fe | iron |
| FUL | federal upper limit |
| GAHT | gender-affirming hormone therapy |
| GFR | glomerular filtration rate |
| GHB | gamma-hydroxybutyrate |
| GI | gastrointestinal |
| GnRH | gonadotropin-releasing hormone |
| GVHD | graft versus host disease |
| H2 | histamine type 2 |
| H2RA | H2 receptor antagonist |
| HAND | HIV-associated neurocognitive disorder |
| HAV | hepatitis A virus |
| HbA1C | hemoglobin A1c |
| HBcAb | hepatitis B core antibody |
| HBeAg | hepatitis B e antigen |
| HBsAb | hepatitis B surface antibody |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCC | hepatocellular carcinoma |
| HCO3 | bicarbonate |
| HCT | hematopoietic cell transplant |
| HCV | hepatitis C virus |
| HD | hemodialysis high-dose |
| HDL | high-density lipoprotein |
| HDV | hepatitis D virus |
| HHS | U.S. Department of Health and Human Services |
| HIV | human immunodeficiency virus |
| HIV RNA | HIV viral load |
| HIV-1 | human immunodeficiency virus type 1 |
| HIV-2 | human immunodeficiency virus type 2 |
| HIVMA/IDSA | HIV Medicine Association of the Infectious Diseases Society of America |
| HLA | human leukocyte antigen |
| HMG-CoA | hydroxy-methylglutaryl-coenzyme A |
| HR | hazard ratio |
| HRSA | Health Resources and Services Administration |
| HRT | hormone replacement therapy |
| hs-CRP | high-sensitivity C-reactive protein |
| HSR | hypersensitivity reaction |
| HTLV-1 | human T-lymphotropic virus-1 type I |
| IC50 | median inhibitory concentration |
| IL | interleukin |
| IM | intramuscular |
| IMF | illicitly manufactured fentanyl |
| IN | integrase |
| INR | international normalized ratio |
| INSTI | integrase strand transfer inhibitor |
| IPT | isoniazid preventive therapy |
| IRIS | immune reconstitution inflammatory syndrome |
| ISR | injection site reactions |
| IUD | intrauterine device |
| IV | intravenous |
| K | potassium |
| LA | long-acting |
| LDL | low-density lipoprotein |
| LGBTQ | lesbian, gay, bisexual, transgender, or queer |
| LLOD | lower limits of detection |
| LTBI | latent tuberculosis infection |
| MAC | Mycobacterium avium complex |
| MATE | multidrug and toxin extrusion transporter |
| MDMA | methylenedioxymethamphetamine |
| MDR | multidrug resistant |
| MDR-TB | multidrug-resistant tuberculosis |
| MDRP | Medicaid Drug Rebate Program |
| MET | motivational enhancement therapy |
| Mg | magnesium |
| MHC | major histocompatibility complex |
| MI | motivational interviewing myocardial infarction |
| MPA | medroxyprogesterone acetate |
| MRI | magnetic resonance imaging |
| MSM | men who have sex with men |
| MTR | multi-tablet regimen |
| N/A | not applicable |
| Na | sodium |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside/nucleotide reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OATP | organic anion-transporting polypeptide |
| OBR | optimized background regimen |
| OCT2 | organic cation transporter 2 |
| OH-itraconazole | active metabolite of itraconazole |
| OI | opportunistic infection |
| ONDCP | Office of National Drug Control Policy |
| OR | odds ratio |
| OTP | opioid treatment program |
| OUD | opioid use disorder |
| P | phosphorus |
| P-gp | p-glycoprotein |
| PAH | pulmonary arterial hypertension |
| PBM | pharmacy benefit manager |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PDE5 | phosphodiesterase type 5 |
| PEP | post-exposure prophylaxis |
| PI | protease inhibitor |
| PI/c | cobicistat-boosted protease inhibitor |
| PI/r | ritonavir-boosted protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PPI | proton pump inhibitor |
| PR | protease |
| PRAPARE | Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences |
| PrEP | pre-exposure prophylaxis |
| PTH | parathyroid hormone |
| QTc | QT corrected for heart rate |
| REPC | Retention through Enhanced Personal Contact |
| RNA | ribonucleic acid |
| RT | reverse transcriptase |
| RWHAP | Ryan White HIV/AIDS Program |
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SCr | serum creatinine |
| SDOH | social determinants of health |
| SMR | sexual maturity rating |
| SOT | solid organ transplantation |
| SPT | skin patch test |
| SQ | subcutaneous |
| SSP | syringe service program |
| SSRI | selective serotonin reuptake inhibitor |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| SUD | substance use disorder |
| TasP | treatment as prevention |
| TB | tuberculosis |
| TC | total cholesterol |
| TCA | tricyclic antidepressant |
| TDM | therapeutic drug monitoring |
| TDR | transmitted drug resistance |
| TG | triglyceride |
| The Panel | The Panel on Antiretroviral Guidelines for Adults and Adolescents |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1 | uridine diphosphate glucuronosyltransferase 1 family |
| UGT1A1 | uridine diphosphate glucuronosyltransferase 1A1 |
| ULN | upper limit of normal |
| UW | University of Washington |
| VL | viral load |
| VPA | valproic acid |
| WAC | wholesale acquisition cost |
| WBC | white blood cell |
| WHO | World Health Organization |
| WPATH | World Professional Association for Transgender Health |
| XDR | extensively drug-resistant |
| XR | extended release |
| Zn | zinc |
Download Guidelines
- Section Only PDF (88.31 KB)
- Full Guideline PDF (5.5 MB)
- Recommendations Only PDF (239.25 KB)
- Tables Only PDF (2.19 MB)